Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $745.46K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $2.24M.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $745.46K or moves back toward the trailing-twelve-month quarterly average of $560.3K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$745.46K-1.1% QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$2.24M+39.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How INO compares with its peers on the latest reported figures

  • INO's LTM Mar 2026 cost of revenue of $2.24M is the 6th highest of the 10 companies compared; the peer median is $6.04M.
  • Its year-over-year change of +39.7% is the highest of 9, against a peer median of -58.8%.
INO Competitors Peer median
Cost of Revenue for INO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$59.29M -55.6%-25.9%47.9%
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M -62.0%-2.1%515.8%
ALECAlector, Inc.LTM Mar 2026$29.7M -64.0%—161.2%
SEERSeer, Inc.LTM Mar 2026$7.78M -27.0%-0.2%51.7%
IRDOpus Genetics, Inc.LTM Mar 2026$6.04M -22.4%—50.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.24M +39.7%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026$1.39M -86.2%—120.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$46K +4.5%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
Peer median (excluding INO) $6.04M-58.8%-2.1%51.7%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77M10.26M832.01K217.76K65.34K
Cost of Revenue00000
Gross Profit1.77M10.26M832.01K217.76K65.34K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development249.24M187.65M86.68M75.62M54.21M
Selling, General & Admin53.75M90.19M47.58M37M32.68M
Operating Expenses302.99M277.84M144.77M112.62M86.89M
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
EBITDA(296.56M)(270.9M)(130.39M)(103.95M)(81.96M)
EBITDA Margin-16709.7%-2639.8%-15671.8%-47735.2%-125425.9%
Operating Income(301.22M)(267.57M)(143.94M)(112.4M)(86.82M)
Operating Margin-16972.3%-2607.4%-17300.3%-51616.9%-132871.3%
Interest Income3.36M4.78M8.13M4.77M2.42M
Interest Expense1.94M1.25M1.22M177.83K0
Other Income / Expenses(2.44M)(12.24M)8.82M5.14M1.88M
Income Before Tax(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Pre-Tax Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
Income Tax Expense00000
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Net Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
EPS (Basic)(1.42)(14.07)(6.09)(3.95)(1.81)
EPS (Diluted)(1.42)(14.07)(6.09)(3.95)(1.81)
Weighted Avg Shares214.62M19.89M22.17M27.16M468.86M
Weighted Avg Shares (Diluted)214.62M19.89M22.17M27.16M468.86M

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.